Australian firm Ramsey Healthcare have agreed to buy Elysium Healthcare for $1.03bn (£775m). The deal will add 72 mental healthcare focused sites to their portfolio and is rumoured to have been transacted at around 13-14X EBITDA.

As with The Huntercombe Group acquisition within The Montreux Healthcare Fund portfolio, mental healthcare services are seen as even more important with the current threats to mental wellbeing during and post the COVID 19 pandemic. For this reason, the government has committed an additional £2.3bn in 2023-2024.

Oliver Harris, Managing Partner, Montreux Capital Management (UK) stated: “Our investors are often curious about transactions in the market and this latest deal signals the ongoing strength of investing within the UK healthcare sector. This asset is a similar size to the group my team is endeavouring to build and demonstrates the appetite for businesses of this scale in the market and the types of attractive multiples that they trade at. Global investors will always pay a premium for high quality assets, particularly those that have demonstrated a strong track record during the pandemic.”

Find Us

Thameside House
Hurst Road
East Molesey

T: + 44 (0) 1932 860 140

Information on this webpage relates to and is provided by Montreux Capital Management (UK) Limited

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management (UK) Limited and Sapia Partners LLP (together “the Sponsors,” or “Sponsor”) do not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

Montreux Capital Management (UK) Limited is an Appointed Representative of Sapia Partners LLP which is authorised and regulated by the Financial Conduct Authority.